Problem Or Issue:
Important Safety Information communication from Bayer Ltd., Boehringer Ingelheim Ltd., Bristol-Myers Squibb Pharmaceuticals uc, Daiichi Sankyo Ireland Ltd. and Pfizer Healthcare Ireland: Eliquis (apixaban), Pradaxa (dabigatran etexilate), ▼ Lixiana (edoxaban), ▼ Xarelto (rivaroxaban) are not recommended in patients with antiphospholipid syndrome due to possible increased risk for recurrent thrombotic events
Important Safety Information - Eliquis (apixaban), Pradaxa (dabigatran etexilate), ▼ Lixiana (edoxaban), ▼ Xarelto (rivaroxaban)